BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11304577)

  • 1. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma.
    Kang JH; Kim SJ; Noh DY; Park IA; Choe KJ; Yoo OJ; Kang HS
    Lab Invest; 2001 Apr; 81(4):573-9. PubMed ID: 11304577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter CpG island hypermethylation during breast cancer progression.
    Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
    Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
    Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
    Muggerud AA; Rønneberg JA; Wärnberg F; Botling J; Busato F; Jovanovic J; Solvang H; Bukholm I; Børresen-Dale AL; Kristensen VN; Sørlie T; Tost J
    Breast Cancer Res; 2010; 12(1):R3. PubMed ID: 20056007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
    Nass SJ; Herman JG; Gabrielson E; Iversen PW; Parl FF; Davidson NE; Graff JR
    Cancer Res; 2000 Aug; 60(16):4346-8. PubMed ID: 10969774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
    Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS
    J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer.
    Tommasi S; Karm DL; Wu X; Yen Y; Pfeifer GP
    Breast Cancer Res; 2009; 11(1):R14. PubMed ID: 19250546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Promoter methylation and mRNA expression of WT1 gene in MCF10 breast cancer model].
    Yang JL; Klinkebiel D; Boland MJ; Tang L; Christman JK
    Zhonghua Bing Li Xue Za Zhi; 2007 Apr; 36(4):253-8. PubMed ID: 17706117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of promoter hypermethylation in laser-microdissected archival specimens.
    Lehmann U; Hasemeier B; Lilischkis R; Kreipe H
    Lab Invest; 2001 Apr; 81(4):635-8. PubMed ID: 11304583
    [No Abstract]   [Full Text] [Related]  

  • 11. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
    Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
    Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
    Moelans CB; Verschuur-Maes AH; van Diest PJ
    J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in CpG islands promoter methylation patterns during ductal breast carcinoma progression.
    Hoque MO; Prencipe M; Poeta ML; Barbano R; Valori VM; Copetti M; Gallo AP; Brait M; Maiello E; Apicella A; Rossiello R; Zito F; Stefania T; Paradiso A; Carella M; Dallapiccola B; Murgo R; Carosi I; Bisceglia M; Fazio VM; Sidransky D; Parrella P
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2694-700. PubMed ID: 19789364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer.
    Wang D; Li C; Zhang X
    DNA Cell Biol; 2014 Sep; 33(9):581-90. PubMed ID: 24842653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation.
    Pogribny IP; James SJ
    Cancer Lett; 2002 Feb; 176(2):169-74. PubMed ID: 11804744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.
    Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P
    Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Methylation status and protein expression of adenomatous polyposis coli (APC) gene in breast cancer].
    Liu Z; Yang L; Cui DX; Liu BL; Zhang XB; Ma WF; Zhang Q
    Ai Zheng; 2007 Jun; 26(6):586-90. PubMed ID: 17562262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.
    Fleischer T; Frigessi A; Johnson KC; Edvardsen H; Touleimat N; Klajic J; Riis ML; Haakensen VD; Wärnberg F; Naume B; Helland A; Børresen-Dale AL; Tost J; Christensen BC; Kristensen VN
    Genome Biol; 2014; 15(8):435. PubMed ID: 25146004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers.
    Zhang X; Sun Q; Shan M; Niu M; Liu T; Xia B; Liang X; Wei W; Sun S; Zhang Y; Liu XS; Song Q; Yang Y; Ma Y; Liu Y; Yang L; Ren Y; Zhang G; Pang D
    PLoS One; 2013; 8(1):e53931. PubMed ID: 23349767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.